492 results on '"Turecek, Peter L."'
Search Results
2. Real-world treatment of patients with severe congenital protein C deficiency with protein C concentrate: A physician survey
3. Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma
4. Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII
5. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor
6. The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A
7. Macrophage Galactose Lectin Contributes to the Regulation of FVIII (Factor VIII) Clearance in Mice
8. Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine
9. Clinical use of thrombin generation assays
10. A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B
11. Polysialic Acid-Mediated Activity Measurement of Polysialylated Recombinant Coagulation Factor VIII
12. Polysialylation of human coagulation factor VIII
13. Contributors
14. PEG–protein conjugates
15. Selective functional activity measurement of a PEGylated protein with a modification-dependent activity assay
16. In vitro field study and worldwide survey assessing how clinical haemostasis laboratories analyse recombinant and plasma‐derived von Willebrand factor products.
17. Anti-drug antibodies against the PEG moiety inhibit the procoagulant activity of therapeutic PEGylated FVIII
18. PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs
19. Low ADAMTS13 activity is associated with an increased risk of ischemic stroke
20. FVIII concentrate half-life heterogeneity in patients with haemophilia A is due to variability in endogenous VWF clearance.
21. Development of a lectin binding assay to differentiate between recombinant and endogenous proteins in pharmacokinetic studies of protein-biopharmaceuticals
22. Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease
23. A cross‐sectional follow‐up study of physical activity in adults with moderate and severe haemophilia.
24. Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages
25. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial
26. Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease
27. A Flow-Cytometry-Based Approach to Facilitate Quantification, Size Estimation and Characterization of Sub-visible Particles in Protein Solutions
28. Ca2+ concentration-dependent conformational change of FVIII B-domain observed by atomic force microscopy
29. Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
30. Plasma procurement and plasma product safety in light of the COVID ‐19 pandemic from the perspective of the plasma industry
31. PEGylated recombinant von Willebrand factor analyzed by means of MALDI-TOF-MS, CGE-on-a-chip and nES-GEMMA
32. Visualization of a protein-protein interaction at a single-molecule level by atomic force microscopy
33. Physical activity, physical fitness and cardiometabolic risk amongst adults with moderate and severe haemophilia.
34. Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B
35. GEMMA and MALDI-TOF MS of reactive PEGs for pharmaceutical applications
36. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development
37. Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes
38. Reply to Farrugia: Appropriately specifying the quality of plasma for fractionation
39. Biochemical and cellular markers differentiate recovered, in‐line filtered plasma, and plasma obtained by apheresis methods
40. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19
41. 20 - Polysialylation of human coagulation factor VIII
42. 8 - PEGylation of human coagulation factor VIII and other plasma proteins
43. 4 - PEG–protein conjugates: nonclinical and clinical toxicity considerations
44. Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study.
45. Convenient high-resolution isoelectric focusing (IEF) method for the separation of alpha1-proteinase inhibitor (A1PI) isoforms in A1PI concentrates
46. In vivo and in vitro processing of recombinant pro-von Willebrand factor
47. Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage
48. Genotyping of the prion protein gene at codon 129
49. Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors
50. Preclinical Testing of Human Recombinant von Willebrand Factor: ADAMTS13 Cleavage Capacity in Animals as Criterion for Species Suitability
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.